Legend Biotech Stock News

Here's why our roundtable loves Legend Biotech, Heron Therapeutics, and Pieris Pharmaceuticals.

Legend Biotech's IPO was among the Top five largest of 2020. Compared to the other four, Legend's share price has performed exceptionally well.

The treatment, Carvykti/Cilta-cel, belongs to a class of drugs known as CAR-T therapies, or chimeric antigen receptor T-cell therapies

Shares of Legend Biotech Corp. were up 8.6% in premarket trading on Tuesday, the day after the company said that the Food and Drug Administration had approved the CAR-T therapy it developed with Johnson & Johnson as a multiple myeloma treatment. J&J''s stock was down 0.8% in premarket trading on Tuesday. Legend had inked the licensing and collaboration deal with J&J back in 2017. The treatment is approved for adults with relapsed or refractory multiple myeloma who have already received four lines of treatment. The "approval of Carvykti is a pivotal moment for Legend Biotech because it is our first-ever marketing approval, but what really excites us is the drug''s potential to become an impactful therapy option for patients in need of long, treatment-free intervals," Ying Huang, Legend''s CEO and CFO, said in a news release. Legend''s stock has soared 49.8% over the past year, while the broader S&P 500 is up 14.7%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move.

The FDA has approved Legend Biotech Corporation''s (NASDAQ: LEGN ) first product, Carvykti (ciltacabtagene autoleucel; cilta-cel), for relapsed or refractory multiple myeloma. The approval covers adult patients who have received four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. Legend Biotech entered into … Full story available on Benzinga.com

The U.S. Food and Drug Administration ((FDA)) approved Johnson & Johnson (JNJ) and Legend Biotech''s (LEGN) CAR-T therapy Carvykti to treat adults with relapsed or refractory…

The U.S. health regulator has approved a therapy developed by Johnson & Johnson and its China-focused partner Legend Biotech Corp to treat a type of white blood cell cancer, the U.S. healthcare company said on Monday.

The FDA has approved a new CAR-T cancer therapy developed by Janssen and Legend Biotech to treat multiple myeloma.

Legend Biotech (LEGN) has reported preliminary results for 2021, expecting loss of ~$365.3M to $397.4M and adj. loss of $335.8M to $364.7M.As of Dec

The FDA has instituted a clinical hold on Legend Biotech Corporation''s (NASDAQ: LEGN ) Phase 1 trial for LB1901. LB1901 is the company''s investigational autologous chimeric antigen receptor T-cell (CAR-T) therapy targeting malignant CD4+ T-cells for relapsed or refractory T-cell lymphoma (TCL). The … Full story available on Benzinga.com

Legend Biotech (LEGN) is trading ~6% lower in the pre-market on Tuesday after the company announced that the U.S Food and Drug Administration ((FDA)) imposed a clinical hold on its Phase…

The FDA has instituted a clinical hold on Legend Biotech Corporation's (NASDAQ: LEGN) Phase 1 trial for LB1901.  LB1901 is the company's investigational autologous chimeric antigen receptor T-cel

Legend Biotech (LEGN) announced the achievement of two milestones under its collaboration with Janssen Biotech of Johnson & Johnson (JNJ) for cilta-cel.Also called…

Legend Biotech Co. (NASDAQ:LEGN) Equities researchers at Piper Sandler issued their FY2021 EPS estimates for Legend Biotech in a report released on Tuesday, December 21st. Piper Sandler analyst E. Tenthoff anticipates that the company will post earnings of ($1.39) per share for the year. Piper Sandler currently has a Overweight rating and a $66.00 [] The post Piper Sandler Comments on Legend Biotech Co.s FY2021 Earnings (NASDAQ:LEGN) appeared first on ETF Daily News .

Vontobel Holding Ltd. lessened its stake in shares of Legend Biotech Co. (NASDAQ:LEGN) by 12.7% during the 3rd quarter, Holdings Channel reports. The fund owned 34,147 shares of the companys stock after selling 4,962 shares during the quarter. Vontobel Holding Ltd.s holdings in Legend Biotech were worth $1,726,000 at the end of the most recent []